Pharmacology · ANS Introduction

Autonomic Receptors: Classification, Signaling, and Tissue Distribution

Muscarinic, nicotinic, and adrenergic receptor subtypes — G-protein coupling, tissue locations, and key drugs

Muscarinic receptors (M1–M5) are all GPCRs: M1, M3, and M5 couple to Gq (excitatory, via IP3/DAG); M2 and M4 couple to Gi (inhibitory, reducing cAMP) — M2 on the heart slows rate and conduction, while M3 on smooth muscle and glands mediates most peripheral parasympathetic effects including bronchoconstriction and secretion.
Nicotinic receptors are ligand-gated ion channels, not GPCRs — N-N receptors at autonomic ganglia depolarize postganglionic neurons in both divisions; N-M receptors at the motor endplate trigger skeletal muscle contraction; succinylcholine is a depolarizing agonist at N-M that produces paralysis by persistent depolarization.
Adrenergic receptor selectivity determines therapeutic strategy: alpha-1 (Gq) blockade causes vasodilation (prazosin) and urinary relaxation (tamsulosin); alpha-2 (Gi) agonism lowers sympathetic outflow centrally (clonidine); beta-1 (Gs) selective blockade reduces cardiac rate and contractility; beta-2 (Gs) selective agonism produces bronchodilation without cardiac effects.
Beta-3 receptors (Gs) on the bladder detrusor mediate relaxation — mirabegron, a selective beta-3 agonist, treats overactive bladder without the antimuscarinic side effects of older agents; beta-3 on adipose tissue mediates lipolysis.
Chronic agonist exposure desensitizes GPCRs (minutes: GRK phosphorylation → arrestin binding) and then downregulates them (hours: internalization); chronic antagonist blockade causes compensatory upregulation — abrupt beta-blocker withdrawal causes rebound tachycardia from upregulated beta-1 receptors, requiring slow tapering.

Abbreviations: GPCR = G-protein-coupled receptor · Gq = Gq protein (excitatory) · Gi = Gi protein (inhibitory) · Gs = Gs protein (stimulatory) · GRK = G-protein-coupled receptor kinase · IP3 = inositol trisphosphate · cAMP = cyclic AMP · SA = sinoatrial · AV = atrioventricular

Muscarinic Receptors (G-Protein-Coupled)

Subtype	G-Protein	Primary Location	Effect of Activation	Key Drugs
M1	Gq	CNS neurons, autonomic ganglia	Cognitive facilitation; gastric acid secretion	Pirenzepine (antagonist, peptic ulcer — limited use)
M2	Gi	Heart (SA/AV nodes)	Bradycardia, slowed AV conduction	Atropine (antagonist — raises heart rate)
M3	Gq	Smooth muscle, glands, iris sphincter	Bronchoconstriction, secretion, miosis, bladder contraction	Pilocarpine (agonist — glaucoma); tiotropium, ipratropium (antagonist — COPD)
M4	Gi	CNS striatum	Dopaminergic modulation	Xanomeline-trospium (M1/M4 — schizophrenia)
M5	Gq	CNS (limited)	Dopaminergic neuron modulation	No selective clinical drugs currently

Nicotinic Receptors (Ligand-Gated Ion Channels)

N-N Subtype

Ganglionic Nicotinic

LocationAll autonomic ganglia; adrenal medulla chromaffin cells

EffectDepolarizes postganglionic neuron; triggers catecholamine release from adrenal medulla

AgonistNicotine (low dose); acetylcholine

AntagonistTrimethaphan, mecamylamine — bilateral autonomic blockade

N-M Subtype

Neuromuscular Nicotinic

LocationSkeletal muscle motor endplate only

EffectEndplate depolarization → skeletal muscle contraction

AgonistSuccinylcholine (depolarizing blocker — paralysis by sustained depolarization)

AntagonistRocuronium, vecuronium (non-depolarizing — reversed by neostigmine/sugammadex)

Adrenergic Receptors (G-Protein-Coupled)

Subtype	G-Protein	Primary Location	Effect of Activation	Key Drugs
α1	Gq	Vascular smooth muscle, iris dilator, prostate	Vasoconstriction, mydriasis, urethral contraction	Phenylephrine (agonist); prazosin, tamsulosin (antagonist)
α2	Gi	Presynaptic terminals; CNS; platelets	Reduces NE release; central sympatholysis; platelet aggregation	Clonidine (agonist — antihypertensive); yohimbine (antagonist)
β1	Gs	Heart (SA/AV/ventricle); kidney (JG cells)	Increased rate, conduction, contractility; renin release	Dobutamine (agonist); metoprolol, atenolol (selective antagonist)
β2	Gs	Bronchial smooth muscle; skeletal muscle vessels; uterus	Bronchodilation; vasodilation; uterine relaxation	Albuterol, salmeterol (agonist — asthma); terbutaline (tocolytic)
β3	Gs	Adipose; bladder detrusor	Lipolysis; bladder relaxation	Mirabegron (agonist — overactive bladder)

Receptor Regulation

Process 1

Desensitization

Minutes. GRK phosphorylates receptor → arrestin binds → uncouples from G-protein. Receptor remains on surface, not signaling. Reversible.

Process 2

Downregulation

Hours to days. Receptor internalized into endosomes → degraded or recycled. Net loss of surface receptors. Clinical example: beta-2 agonist tolerance with overuse.

Process 3

Upregulation

Chronic antagonist blockade → compensatory increase in receptor number. Abrupt beta-blocker withdrawal → rebound tachycardia from upregulated beta-1 receptors. Always taper.

Suggested References

Author / Organization	Title	Source
Katzung BG (ed)	Basic and Clinical Pharmacology, 15th ed. Chapters 6–9: Autonomic Nervous System Pharmacology	McGraw-Hill, 2021
Brunton LL, Knollmann BC (eds)	Goodman and Gilman's The Pharmacological Basis of Therapeutics, 14th ed. Chapter 8: Neurotransmission: The Autonomic and Somatic Motor Nervous Systems	McGraw-Hill, 2023
Caulfield MP, Birdsall NJM	International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors	Pharmacol Rev. 1998;50(2):279–290
Harvey RD, Belevych AE	Muscarinic regulation of cardiac ion channels	Br J Pharmacol. 2003;139(6):1074–1084
Wess J, Eglen RM, Gautam D	Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development	Nat Rev Drug Discov. 2007;6(9):721–733
Sine SM	End-plate acetylcholine receptor: structure, mechanism, pharmacology, and disease	Physiol Rev. 2012;92(3):1189–1234
Naguib M, Lien CA, Aker J	Neuromuscular physiology and pharmacology. In: Miller's Anesthesia, 8th ed.	Elsevier Saunders, 2015:423–468
Benowitz NL	Nicotine addiction	N Engl J Med. 2010;362(24):2295–2303
Michel MC, Vrydag W	Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate	Br J Pharmacol. 2006;147(Suppl 2):S88–S119
Brede M, Philipp M, Knaus A, et al	Alpha2-adrenergic receptor subtypes — novel functions uncovered in gene-targeted mouse models	Biol Cell. 2004;96(5):343–348
Bristow MR	Beta-adrenergic receptor blockade in chronic heart failure	Circulation. 2000;101(5):558–569
Johnson M	Molecular mechanisms of beta2-adrenergic receptor function, response, and regulation	J Allergy Clin Immunol. 2006;117(1):18–24
Andersson KE	Beta-adrenoceptors and their role in the regulation of lower urinary tract function	Acta Pharmacol Sin. 2022;43(11):2741–2751
Lohse MJ, Benovic JL, Caron MG, Lefkowitz RJ	Multiple pathways of rapid beta2-adrenergic receptor desensitization	J Biol Chem. 1990;265(6):3202–3211
Vallone D, Picetti R, Borrelli E	Structure and function of dopamine receptors	Neurosci Biobehav Rev. 2000;24(1):125–132
Seeman P	Atypical antipsychotics: mechanism of action	Can J Psychiatry. 2002;47(1):27–38
Wehrwein EA, Orer HS, Barman SM	Overview of the anatomy, physiology, and pharmacology of the autonomic nervous system	Compr Physiol. 2016;6(3):1239–1278
Eglen RM	Muscarinic receptor subtype pharmacology and physiology	Prog Med Chem. 2005;43:105–136